Bristol Earnings Feature Downside Disclosures But Still Rely On Restructuring
Executive Summary
Bristol is signaling another round of restructuring for the end of 2003 as it prepares for the next wave of patent expirations
You may also be interested in...
Bristol Medicaid subpoena
Bristol-Myers Squibb "best price" reporting requirements under Medicaid are the subject of a subpoena from Massachusetts U.S. Attorney's Office, company says in Securities & Exchange Commission filing Aug. 8. Bristol recently commenced an "internal review" to determine whether Medicaid rebates and pricing practices have been appropriate (1"The Pink Sheet" July 28, 2003, p. 33). Bristol met with Boston U.S. Attorney's Office to "discuss the review and its plan for sharing the results of the review," filing says. The company "subsequently received a subpoena...relating to the subject matter of the review"...
Bristol Medicaid subpoena
Bristol-Myers Squibb "best price" reporting requirements under Medicaid are the subject of a subpoena from Massachusetts U.S. Attorney's Office, company says in Securities & Exchange Commission filing Aug. 8. Bristol recently commenced an "internal review" to determine whether Medicaid rebates and pricing practices have been appropriate (1"The Pink Sheet" July 28, 2003, p. 33). Bristol met with Boston U.S. Attorney's Office to "discuss the review and its plan for sharing the results of the review," filing says. The company "subsequently received a subpoena...relating to the subject matter of the review"...
Bristol Restates, But Reforms Continue; Q3 Charges Show Old Habits Die Hard
Bristol is taking steps to create a more open environment for internal communications as part of ongoing reforms to its financial controls